Antitumor Effects of JAK3 Inhibitor on the Model of Transplantable Lewis Lung Carcinoma and Mechanisms of Their Development
- Authors: Zyuz’kov G.N.1,2, Amosova E.N.1, Chaikovskii A.V.1, Miroshnichenko L.A.1, Udut E.V.1, Rybalkina O.Y.1, Zhdanov V.V.1, Udut V.V.1,2, Dygai A.M.1, Zueva E.P.1
- 
							Affiliations: 
							- E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
- Laboratory of Physical Processes Modeling in Biology and Medicine, National Research Tomsk State University
 
- Issue: Vol 161, No 3 (2016)
- Pages: 367-370
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/237421
- DOI: https://doi.org/10.1007/s10517-016-3415-1
- ID: 237421
Cite item
Abstract
Mice with Lewis lung carcinoma were used to study the antitumor and antimetastatic effects of JAK3 inhibitor. The study revealed no effect of JAK3 inhibitor on the growth of primary tumor node, but found a pronounced inhibition of hematogenous spread of the pathologic process into the lungs. In vitro blockade of JAK3 in cultured Lewis lung carcinoma produced no effect on the count of the stem tumor cells and stimulated functions of committed elements. In addition, blockade of JAK3 significantly elevated maturation index of the tumor tissue.
About the authors
G. N. Zyuz’kov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine; Laboratory of Physical Processes Modeling in Biology and Medicine, National Research Tomsk State University
							Author for correspondence.
							Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk; Tomsk						
E. N. Amosova
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
A. V. Chaikovskii
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
L. A. Miroshnichenko
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
E. V. Udut
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
O. Yu. Rybalkina
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
V. V. Zhdanov
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
V. V. Udut
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine; Laboratory of Physical Processes Modeling in Biology and Medicine, National Research Tomsk State University
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk; Tomsk						
A. M. Dygai
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
E. P. Zueva
E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine
														Email: zgn@pharm.tsu.ru
				                					                																			                												                	Russian Federation, 							Tomsk						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					